Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ESR1Real World Assessment Prevalence Study

NCT07817212 is registered in ClinicalTrials.gov with Institut fuer Frauengesundheit as lead sponsor.

NCT NCT07817212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07817212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ESR1Real World Assessment Prevalence Study
Lead sponsor
Institut fuer Frauengesundheit
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2027
Enrollment
1,550 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2- abc undergoing 1l treatment with cdk4/6i (palbociclib, abemaciclib or ribociclib) and ai (anastrozole or letrozole)